Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
2019, Journal of Gerontological Nursing
…
3 pages
1 file
Pain physician, 2006
Opioid abuse has increased at an alarming rate. However, available evidence suggests a wide variance in the use of opioids, as documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration (DEA). The objective of these opioid guidelines by the American Society of Interventional Pain Physicians (ASIPP) is to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to bring consistency in opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of drug diversion. A policy committee evaluated a systematic review of the available literature regarding opioid use in managing chronic non-cancer pain. This resulted in the formulation of the essentials of guidelines, a series of potential evidence linkages representing conclusions, followed by statements regarding relationships between clinical interventions and outcomes. Consi...
Journal of Gerontological Nursing, 2016
MMWR. Recommendations and Reports, 2016
for conducting initial peer reviews of the guideline for the CDC prior to journal submission; peer reviewers were not compensated for their contributions. We acknowledge Don Teater, MD, for facilitating the Core Expert Group. We acknowledge the work that the medical writers, editors, and reviewers from Ariande Labs provided to produce the checklist for prescribing opioids for chronic pain.
The Journal of Pain, 2010
This document reports the consensus of an interdisciplinary panel of research and clinical experts charged with reviewing the use of opioids for chronic noncancer pain (CNCP) and formulating guidelines for future research. Prescribing opioids for chronic noncancer pain has recently escalated in the United States. Contrasting with increasing opioid use are: 1) The lack of evidence supporting long-term effectiveness; 2) Escalating misuse of prescription opioids including abuse and diversion;
The Journal of Pain, 2009
Chronic noncancer pain is common and use of opioids is increasing. Previously published guidelines on use of opioids for chronic noncancer pain have been based primarily on expert consensus due to lack of strong evidence. We conducted searches on Ovid MEDLINE and the Cochrane databases through July 2008 to identify studies that addressed one or more of 37 Key Questions that a multidisciplinary expert panel identified as important to be answered to generate evidence-based recommendations on the use of opioids for chronic noncancer pain. A total of 14 systematic reviews, 38 randomized trials not included in a previously published systematic review, and 13 other studies met inclusion criteria. Almost all of the randomized trials of opioids for chronic noncancer pain were short-term efficacy studies. Critical research gaps on use of opioids for chronic noncancer pain include: lack of effectiveness studies on longterm benefits and harms of opioids (including drug abuse, addiction, and diversion); insufficient evidence to draw strong conclusions about optimal approaches to risk stratification, monitoring, or initiation and titration of opioid therapy; and lack of evidence on the utility of informed consent and opioid management plans, the utility of opioid rotation, the benefits and harms specific to methadone or higher doses of opioids, and treatment of patients with chronic noncancer pain at higher risk for drug abuse or misuse.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2017
C hronic noncancer pain includes any painful condition that persists for at least three months and is not associated with malignant disease. 1 According to seven national surveys conducted between 1994 and 2008, 15%-19% of Canadian adults live with chronic noncancer pain. 2 Chronic noncancer pain interferes with activities of daily living, has a major negative impact on quality of life and physical function, 3 and is the leading cause of health resource utilization and disability among workingage adults. 4,5 In North America, clinicians commonly prescribe opioids for acute pain, palliative care (in particular, for patients with cancer) and chronic noncancer pain. Canada has the second highest rate per capita of opioid prescribing in the world when measured using defined daily doses, and the highest when defined using morphine equivalents dispensed, with more than 800 morphine equivalents per capita in 2011. 6,7 Substantial risks accompany the use of opioids in chronic noncancer pain. In Ontario, admissions to publicly funded treatment programs for opioid-related problems doubled from 2004 to 2013, from 8799 to 18 232. 8,9 Among Ontarians receiving social assistance, 1 of every 550 patients started on chronic opioid therapy died of opioid-related causes at a median of 2.6 years from the first opioid prescription, while 1 in 32 of those receiving 200 mg morphine equivalents daily (MED) or more died of opioid-related causes. 10 An estimated 2000 Canadians died from opioid-related poisonings in 2015 11 and initial numbers for 2016 are higher, with most deaths attributed to fentanyl. 12 In 2010, the National Opioid Use Guideline Group offered recommendations for safe and effective use of opioids. 13 Many of the recommendations were nonspecific and almost all supported the prescribing of opioids; the guideline provided few suggestions about when not to prescribe. 11 A time-series analysis in Ontario, Canada, from 2003 to 2014, found a slight decline in overall opioid prescribing, but no change in rates of fatal opioid overdose and increases in both high-dose opioid prescribing and opioid-related hospital visits. Moreover, 40% of recipients of long-acting opioids received > 200 mg MED, and 20% received > 400 mg MED. 14 This updated guideline incorporates all new evidence published subsequent to the literature search that was used to inform the 2010 guideline. It adheres to standards for trustworthy guidelines 15 and aspires to promote evidence-based prescribing of opioids for chronic noncancer pain. The full guideline is available in Appendix 1 (at www.cmaj.ca/lookup/suppl/
Pain Physician, 2008
Background: Opioid abuse has continued to increase at an alarming rate since our last opioid guidelines were published in 2005. Available evidence suggests a continued wide variance in the use of opioids, as documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration. Objectives: The objectives of opioid guidelines by the American Society of Interventional Pain Physicians (ASIPP) are to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to bring consistency in opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of abuse and drug diversion. Design: A broadly based policy committee of recognized experts in the field evaluated the available literature regarding opioid use in managing chronic non-cancer pain. This resulted in the formulation of the review and update of the guidelines published in 2006, a series of potential evidence linkages representing conclusions, followed by statements regarding the relationships between clinical interventions and outcomes. Methods: The elements of the guideline preparation process included literature searches, literature synthesis, consensus evaluation, open forum presentations, formal endorsement by the Board of Directors of the American Society of Interventional Pain Physicians, and peer review. Based on the criteria of the U.S. Preventive Services Task Force, the quality of evidence was designated as Level I, II, and III, with 3 subcategories in Level II, with Level I described as strong and Level III as indeterminate. The recommendations were provided from 1A to 2C, varying from strong recommendation with high quality evidence to weak recommendation with low-quality or very low-quality evidence. Results: After an extensive review and analysis of the literature, which included systematic reviews and all of the available literature, the evidence for the effectiveness of long-term opioids in reducing pain and improving functional status for 6 months or longer is variable. The evidence for transdermal fentanyl and sustained-release morphine is Level II-2, whereas for oxycodone the level of evidence is II-3, and the evidence for hydrocodone and methadone is Level III. There is also significant evidence of misuse and abuse of opioids. The recommendation is 2A-weak recommendation, high-quality evidence: with benefits closely balanced with risks and burdens; with evidence derived from RCTs without important limitations or overwhelming evidence from observational studies, with the implication that with a weak recommendation, best action may differ depending on circumstances or patients' or societal values. Conclusion: Opioids are commonly prescribed for chronic non-cancer pain and may be effective for short-term pain relief. However, long-term effectiveness of 6 months or longer is variable with evidence ranging from moderate for transdermal fentanyl and sustained-re
Behavioural Public Policy, 2023
مجله پژوهش های باستان شناسی ایران, 2024
Jurnal Teknologi Sistem Informasi, 2021
Doctoral thesis, 2024
Revista Didática Sistêmica, 2023
Cité interdite, palais impériaux et cours royales. Les symboles du pouvoir impérial et monarchique en Orient et en Occident, 2021
RePEc: Research Papers in Economics, 2009
Proceedings of the International Symposium on Social Sciences, Education, and Humanities (ISSEH 2018), 2019
European Journal of Surgical Oncology (EJSO), 2009
Journal of the Human and Social Science Researches, 2020
Bioprocess and Biosystems Engineering, 2018